A recent study reveals how cellular structures called ‘stress granules’ help cells evade death. The findings may lead to new strategies for improving the efficacy of cancer therapy.
A drug currently in clinical trials as an anticancer agent might also be useful as a treatment for inflammatory and autoimmune diseases. The findings also suggests strategies for using the drug to enhance cancer immunotherapies.
A recent study by Rachelle Johnson, Ph.D., and colleagues looked at factors influencing the ability of breast cancer cells to colonize bone and enter and exit a dormant state.
Patients who received atezolizumab in addition to standard chemotherapy lived two months longer than those treated with chemotherapy alone, according to a recent study published in the New England Journal of Medicine.
In an article recently published in Cell Reports, James G. Patton, PhD, and colleagues studied how colon cancer cells can secrete long RNAs in carefully regulated ways.
Charles Caskey, Ph.D., has received a cancer research grant from The Mary Kay Foundation to study how focused ultrasound therapy could be an ideal helper for immunotherapy.
Angelika Amon, PhD, whose groundbreaking investigations of chromosome segregation during cell division have advanced understanding of how cancer may develop, is the recipient of the 2018 Vanderbilt Prize in Biomedical Science.
Vanderbilt chemists have been awarded $7.2 million over the next five years from the National Cancer Institute to lead an initiative to better understand how a combination chemotherapy for breast cancer targets DNA.
Nashville Predators goaltender Pekka Rinne, Predators executives and executives from Tri Star Energy (Twice Daily) made their annual presentation recently of proceeds from the team’s 365 Pediatric Cancer Fund to Monroe Carell Jr. Children’s Hospital at Vanderbilt.
Vanderbilt-Ingram Cancer Center (VICC) investigators have received financial support from Susan G. Komen for breast cancer research.